



April 17, 2024

**BSE Limited**  
Floor 25, P. J. Towers  
Dalal Street,  
Mumbai - 400 001

**The National Stock Exchange of India Limited**  
Exchange Plaza  
Bandra Kurla Complex, Bandra (E)  
Mumbai - 400 051

**Scrip Code: 530019**

**Symbol: JUBLPHARMA**

Dear Sirs,

In continuation to our letter dated February 3, 2024, we enclose a communication pursuant to Provisions of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Company has received communication from USFDA at 9.11 pm (IST) on April 16, 2024.

We request you to take the same on record.

Thanking you,  
Yours faithfully,

For **Jubilant Pharmova Limited**

**Naresh Kapoor**  
**Company Secretary**  
Encl.: As above

A Jubilant Bhartia Company

OUR VALUES



**Jubilant Pharmova Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
[www.jubilantpharmova.com](http://www.jubilantpharmova.com)

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223  
UP, India  
CIN : L24116UP1978PLC004624



## Jubilant Pharmova Limited

1A, Sector 16A, Noida – 201301, India

Tel.: +91 120 4361000

[www.jubilantpharmova.com](http://www.jubilantpharmova.com)

## **USFDA determines inspection classification of ‘Voluntary Action Indicated’ for the Solid dosage manufacturing facility at Roorkee, India**

**Noida, Apr 17, 2024**, Jubilant Pharmova Limited’s wholly owned subsidiary Jubilant Pharma Limited, today announced that its subsidiary Jubilant Generics Limited (‘JGL’) received a communication from the USFDA through which the regulatory agency intimated that pursuant to its January 25 to February 2, 2024 audit of JGL’s Solid dosage manufacturing facility at Roorkee, India, it has determined the inspection classification of the facility as **“Voluntary Action Indicated (VAI)”**.

Based on this inspection and the USFDA VAI classification, the facility is considered to be in acceptable state of compliance with regard to current good manufacturing practices (cGMP). With this, the FDA has concluded that this inspection is “closed”.

### **About Jubilant Pharma Limited**

Jubilant Pharma Limited (JPL), a Company incorporated under the laws of Singapore and a wholly-owned subsidiary of Jubilant Pharmova Limited, is an integrated global pharmaceutical company engaged in manufacturing and supply of Radiopharmaceuticals with a network of 46 radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Solid Dosage Formulations through five manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. The Company has a team of around 3,200 multicultural people across the globe and is committed to delivering value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally. For more info please visit [www.jubilantpharma.com](http://www.jubilantpharma.com)

### **About Jubilant Pharmova Limited**

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is engaged in Radiopharma, Allergy Immunotherapy, CDMO of Sterile Injectable, Generics, Contract Research Development and Manufacturing (CRDMO) and Proprietary Novel Drugs businesses. With a network of 46 radio-pharmacies in the US, Jubilant’s Radiopharma business is engaged in manufacturing and supply of Radiopharmaceutical products and services. Its other businesses such as Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Generics (Solid Dosage Formulations) caters to major regulated markets (USA, EU and other geographies) through five manufacturing facilities. The CRDMO segment (through Jubilant Biosys) provides collaborative research and partnership for Drug Discovery through two world class research centers in India. The company is also involved in the manufacturing of Active Pharmaceutical Products (API) through a US FDA approved facility in Nanjangud, Karnataka. Jubilant Therapeutics (JTI) invested for in-house Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant Pharmova Limited has a team of over 5,500 multicultural people across the globe. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals companies globally. For more information, please visit: [www.jubilantpharmova.com](http://www.jubilantpharmova.com)

---



## For more information, please contact:

### For Investors

**Pankaj Dhawan**

Phone: +91 120 436 1105

E-mail: [Pankaj.dhawan@jubl.com](mailto:Pankaj.dhawan@jubl.com)

### Siddharth Rangnekar

CDR India

Phone: +91 97699 19966

E-mail: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)

### For Media

**Gaurav Jain**

Phone: +91-120 436 1026

E-mail: [gaurav.jain1@jubl.com](mailto:gaurav.jain1@jubl.com)

### Ryan Marshall

Madison Public Relations

Phone: +91 9810047944

E-mail: [ryan.marshall@madisonpr.in](mailto:ryan.marshall@madisonpr.in)

## Disclaimer

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

